Compounded vs. branded GLP-1: the actual difference, and when one beats the other

The patient question we get more than any other on weight-loss intake: "Is compounded semaglutide actually the same drug as Wegovy?"

Short answer: the active ingredient is identical — same molecule, same mechanism, same downstream effects. The differences are in everything around the active ingredient — the carrier, the production source, the dosing flexibility, the cost, and the regulatory pathway. Some of those differences matter clinically. Most don't.

Here's what's actually going on, what the 2026 regulatory situation looks like, and how to think about which route fits your protocol.

What "compounded" actually means.

A compounded medication is a customized formulation prepared by a licensed compounding pharmacy in response to a clinician's prescription. The active pharmaceutical ingredient (API) is the same as in the branded version. The formulation — concentration, carrier, dose strength, sometimes added ingredients — can vary.

For GLP-1s specifically:

• Compounded semaglutide uses the same semaglutide API as Wegovy and Ozempic.
• Compounded tirzepatide uses the same tirzepatide API as Zepbound and Mounjaro.
• Production happens at FDA-registered 503A or 503B compounding pharmacies.
• The API is sourced from FDA-registered API suppliers (the same source streams that supply API to the branded manufacturers).

The 2024–2026 regulatory backdrop.

Compounded GLP-1s exist as a meaningful market today because both semaglutide and tirzepatide spent multiple years on the FDA Drug Shortage List from 2022 through early 2025. During that window, compounding pharmacies could legally produce compounded versions of those molecules.

The status changed in 2025:

• Tirzepatide was removed from the FDA shortage list in early 2025. The FDA gave 503A pharmacies a 90-day transition window and 503B outsourcing facilities a longer window.
• Semaglutide was removed from the shortage list later in 2025 with similar transition periods.

As of 2026: compounded GLP-1s are still legally produced under specific conditions — primarily when a clinician prescribes a clinically necessary variation (different concentration, combination with another active ingredient like a B vitamin, or a strength not commercially available). The market is real and active, but the regulatory framing is more specific than the "drug shortage" framing of 2022–2024.

What the active ingredient looks like in practice.

The most common compounded GLP-1 formulations:

• Semaglutide: typically 2.5 mg/mL or 5 mg/mL in a multi-dose vial. Stored refrigerated. Drawn into an insulin syringe and self-administered subcutaneously once weekly.
• Tirzepatide: typically 10 mg/mL or 20 mg/mL in a multi-dose vial. Same delivery method.
• Compounded semaglutide + B12 / B6: common combination formulation. The vitamins don't meaningfully change the weight-loss effect but may reduce nausea in some patients.

Self-administration with a syringe is the most common delivery for compounded versions, vs. prefilled auto-injector pens for the branded versions. Both deliver the same active ingredient. The pen is more convenient; the vial is more dose-flexible.

Cost (the honest version).

Approximate 2026 monthly cost ranges:

• Branded Wegovy: $1,300–1,500/month retail, $300–500 with most insurance coverage, $25–250 with high-coverage plans.
• Branded Zepbound: $1,000–1,300/month retail, $250–450 with insurance.
• Compounded semaglutide: typically $200–350/month through telehealth platforms including clinician oversight and labs.
• Compounded tirzepatide: typically $300–450/month with the same inclusions.

For patients without strong insurance coverage, the cost differential is the most significant difference between routes.

What's actually different clinically.

Four real differences:

1. Dosing flexibility. Compounded versions let you titrate in finer increments. Branded pens come in fixed doses (0.25, 0.5, 1.0, 1.7, 2.4 mg for Wegovy; 2.5, 5, 7.5, 10, 12.5, 15 mg for Zepbound). Compounded versions let you stop at 0.6 mg, 1.4 mg, or whatever dose your body actually tolerates. For dose-sensitive patients, this matters.

2. Patient learning curve. Drawing from a vial into a syringe takes 30 seconds and is genuinely simple after a couple of practice sessions — but it's a step the branded auto-injectors don't require. Most patients adapt within 1–2 weeks.

3. Regulatory and quality variation. Branded products are FDA-approved through the new-drug pathway with all the manufacturing oversight that involves. Compounded products are regulated through pharmacy compounding rules — meaningful, but a different (typically less stringent) oversight regime. Choosing a reputable platform working with established 503A or 503B pharmacies matters more in the compounded route.

4. Clinical pairing. Some compounded formulations include B12, glycine, or other co-administered ingredients. These don't change the weight-loss effect, but a small subset of patients tolerate them better.

When branded is the right call.

• You have strong insurance coverage that brings the branded cost under $100/month.
• You strongly prefer the auto-injector pen experience over drawing from a vial.
• You're in a clinical situation (significant comorbidities, complex medication regimen) where the more controlled supply chain of branded medication is worth the cost differential.
• Your clinician specifically recommends it for your case.

When compounded is the right call.

• You don't have insurance coverage that meaningfully reduces the branded cost.
• You want or need finer dose-titration than the branded pens allow.
• You're working through a reputable telehealth platform with US-licensed clinicians and a US-licensed compounding pharmacy.
• The cost differential meaningfully affects whether you can sustain the protocol long-term.

What to avoid, regardless of route.

• "Research peptides" sold for non-human use. These are not pharmaceutical-grade and are not legal for human use. Never mix this market with your prescription medication routine.
• International pharmacies of unverified provenance. The active ingredient may be the real molecule. Or it may not. There's no way to verify without analytical testing.
• Compounded GLP-1s without clinician oversight. Real protocols include intake, dose-escalation guidance, side-effect management, and labs. Anything that skips those steps is a worse bet on the same drug.

The bottom line.

For most patients without strong insurance coverage, compounded semaglutide or tirzepatide through a reputable clinician-supervised platform produces the same clinical result as the branded version at a fraction of the cost. The regulatory framework is more specific in 2026 than it was in 2023, but the core conclusion holds: same active ingredient, different cost, similar outcome — provided the pharmacy and the clinical oversight are real.

Pair this with semaglutide vs. tirzepatide for the molecular choice and GLP-1 maintenance for the back-end protocol.

Same active ingredient, different package, different price. The clinical question isn't compounded-vs-branded — it's whether your provider and pharmacy are real and whether the protocol fits your physiology.

Sources: FDA on compounded drugs and the 503A/503B pathway; FDA drug shortage status updates; Endocrine Society statement on appropriate compounded medication use in obesity.

Editorial disclosure: This article is for informational purposes only and does not constitute medical advice. All treatments at DirectCare AI are prescribed by US-licensed clinicians based on individual medical evaluation. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Always consult a US-licensed clinician before starting or changing any therapy.